Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

Paolo Grassi, Elena Verzoni, Raffaele Ratta, Alessia Mennitto, Filippo de Braud, Giuseppe Procopio Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto nazionale Tumori, Milan, Italy Abstract: The treatment of metastatic renal cell carcinoma (mRCC) has markedly impr...

Full description

Bibliographic Details
Main Authors:	Grassi P, Verzoni E, Ratta R, Mennitto A, de Braud F, Procopio G
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-07-01
Series:	Drug Design, Development and Therapy
Subjects:	cabozantinib XL-184 metastatic renal cell carcinoma VEGF-inhibitor C-Met targeted therapy
Online Access:	https://www.dovepress.com/cabozantinib-in-the-treatment-of-advanced-renal-cell-carcinoma-design--peer-reviewed-article-DDDT

Similar Items

Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy
by: Cierra Hong, et al.
Published: (2021-03-01)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
by: Rupesh Kotecha, et al.
Published: (2021-04-01)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
by: Emeline Colomba, et al.
Published: (2022-10-01)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
by: Sharon Del Vecchio, et al.
Published: (2018-10-01)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
by: Michele Iuliani, et al.
Published: (2021-08-01)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
by: Rathi N, et al.
Published: (2020-05-01)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
by: Debaillon Vesque A, et al.
Published: (2020-06-01)

Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
by: Sylvie Négrier, et al.
Published: (2018-11-01)

Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers
by: Igor Richter, et al.
Published: (2022-03-01)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
by: Matteo Santoni, et al.
Published: (2019-12-01)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
by: Bersanelli M, et al.
Published: (2018-09-01)

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
by: Anastasia A. Sachkova, et al.
Published: (2022-12-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
by: Jingyang Su, et al.
Published: (2024-04-01)

Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study
by: Maria I. Volkova, et al.
Published: (2023-08-01)

Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study
by: Piotr Domański, et al.
Published: (2024-02-01)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
by: Jeffrey Sum-Lung Wong, et al.
Published: (2021-04-01)

Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma
by: Takashi Nakagawa, et al.
Published: (2022-07-01)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
by: Michikata Hayashida, et al.
Published: (2023-11-01)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
by: Thomas Powles, et al.
Published: (2021-08-01)

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
by: Alessia Mennitto, et al.
Published: (2020-03-01)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
by: Hao Wang, et al.
Published: (2022-09-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
by: Jingquan Jia, et al.
Published: (2018-08-01)

Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
by: Koji Iinuma, et al.
Published: (2022-12-01)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
by: Iaxx R, et al.
Published: (2022-06-01)

Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
by: H. M. N. Chen, et al.
Published: (2020-11-01)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
by: SiNi Li, et al.
Published: (2021-12-01)

Contemporary treatment of metastatic renal cell carcinoma
by: Igor Stukalin, et al.
Published: (2016-07-01)

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature
by: Anezka Zemankova, et al.
Published: (2023-07-01)

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
by: Matteo Santoni, et al.
Published: (2021-01-01)

CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure
by: Elodie Coquan, et al.
Published: (2021-09-01)

Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy
by: Rakefet Sidlik Muskatel, et al.
Published: (2022-10-01)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
by: Caroline S. Jansen, et al.
Published: (2023-10-01)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
by: Balázs Jóri, et al.
Published: (2023-09-01)

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report
by: Mehmet A. Bilen, et al.
Published: (2021-02-01)

RET-mutated recurrent leiomyosarcoma treated with cabozantinib: a case report
by: Carlos E. Salazar-Mejía, et al.
Published: (2023-07-01)

Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab
by: Carlos Eduardo Salazar-Mejía, et al.
Published: (2020-12-01)

Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)
by: Eun-mi Yu, et al.
Published: (2023-04-01)

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
by: Shanshan Deng, et al.
Published: (2021-10-01)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
by: Michael H. Storandt, et al.
Published: (2022-10-01)